Developing Medical Device Innovations in 2023, Phapros Realizes the Spirit of Domestic Product Growth.

JAKARTA, December 27th 2022 - PT Phapros Tbk, which is also a member of the state-owned pharmaceutical holding company, will continue its 2022 strategy by supporting the research downstreaming program which is one of the focuses for 2023. According to the President Director of PT Phapros Tbk, Hadi Karodko, the company will strengthen collaboration with universities such as Airlangga University and dr. Soetomo Hospital, Surabaya to develop innovative health devices for teeth and bones.

"Teeth and bones are common diseases suffered by many Indonesians. Although they do not seem like serious diseases, they can have an impact on health and productivity. Phapros sees this as a challenge to provide the forefront solutions to overcome these health disorders. Therefore, we collaborate with researchers from Airlangga University and dr. Soetomo Hospital to create innovative health devices for the community," said Hadi.

Hadi added that the research downstreaming will be done through technology transfer to Phapros' own medical equipment production facilities. "Our target by the end of 2023 is that these medical devices can already be marketed and provide benefits to the community."

As part of the state-owned company, the stock code issuer PEHA is committed to supporting the government's programs related to the health industry. One of the government's concerns is realizing the medical tourism industry which is stipulated in the Cooperation Agreement between the Ministry of Tourism and Creative Economy with the Ministry of Health in the framework of Health Tourism Development.

"To support the government's programs and targets, we take a role in producing research-based drugs and medical equipment collaborations. In the future, we will become a country that has various medical innovations that are not only beneficial for Indonesians but also for other citizens who are seeking treatment with complete facilities," he said optimistically.

In 2022, PT Phapros Tbk has achieved significant growth in terms of sales and market penetration. Flagship products such as Antimo recorded performance of more than 100 percent in the first semester of 2022 and 130 percent until the end of the third quarter. Sales in December are also predicted to grow quite high due to the impact of the Christmas and New Year holidays.

In addition, during 2022 the company also held a number of CSR programs including the distribution of education aid on Sabang Island, Aceh, providing assistance for hydrocephalus patient care in collaboration with the Anne Avantie Foundation, and the Stunting Eradication Movement through the production and distribution of more than 500 million Blood Booster tablets in synergy with all provinces in Indonesia through the Health Department, Schools in several regions, SOEs, and others.